Patents by Inventor Radhakrishnan Rathnachalam

Radhakrishnan Rathnachalam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Anti-Virus VLPS
    Publication number: 20140030792
    Abstract: This invention provides therapeutic viruses (TV) and methods to inhibit the propagation of a target virus. TVs can be rendered noninfectious by inactivating mutations, but also include sequences providing miRNA to inactivate essential mRNAs of the target virus. Methods can include provision of the TV and contact with a host cell harboring the target virus. The target virus providing the essential enzymes necessary to the replication of the TV and the TV disabling the target virus with the miRNA.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 30, 2014
    Inventor: Radhakrishnan Rathnachalam
  • MUTEINS OF FIBROBLAST GROWTH FACTOR 21
    Publication number: 20090118190
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: January 6, 2009
    Publication date: May 7, 2009
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Muteins of fibroblast growth factor 21
    Patent number: 7491697
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: February 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Glycol Linked Fgf-21 Compounds
    Publication number: 20070265200
    Abstract: The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.
    Type: Application
    Filed: March 4, 2005
    Publication date: November 15, 2007
    Applicant: Eli Lilly and Company
    Inventors: Wolfgang Glaesner, Radhakrishnan Rathnachalam, Rohn Millican, Sheng-Hung Tschang
  • Muteins of fibroblast growth factor 21
    Publication number: 20070142278
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 21, 2007
    Inventors: John Beals, Christopher Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Strifler, Radmila Micanovic
  • Flint polypeptide analogs
    Patent number: 6965012
    Abstract: Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: November 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Gerald Wayne Becker, Fredric Jay Cohen, Patricia Ann Gonzalez-DeWhitt, John Edward Hale, Radmila Micanovic, Christy Michelle Newton, Timothy Wayne Noblitt, Radhakrishnan Rathnachalam, Sheng-Hung Rainbow Tschang, Derrick Ryan Witcher, Victor John Wroblewski
  • Agents and methods for the treatment of proliferative diseases
    Patent number: 6867198
    Abstract: The present invention provides selective kinase inhibitors of formula (I)
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: March 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, Kyle Andrew Hecker, James Edward Ray, Jianping Huang, Sajan Joseph, Tiechao Li, Michael Paal, Radhakrishnan Rathnachalam, Chuan Shih, Philip Parker Waid, Xun Zhou, Guoxin Zhu
  • Protease resistant flint analogs
    Patent number: 6835814
    Abstract: The invention relates to FLINT analogs that are to proteolysis in vivo and in vitro at amino acid position 218 of mature FLINT, clinical and therapeutic uses thereof, and pharmaceutical formulations comprising said analogs.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: December 28, 2004
    Assignee: Eli Lilly and Company
    Inventors: Radmila Micanovic, Radhakrishnan Rathnachalam, Derrick Ryan Witcher
  • Hyperglycosylated polypeptides
    Publication number: 20040254351
    Abstract: The present invention addresses the need for better pharmaceutical agents for treating patients that have reduced circulating levels of neutrophilic granulocytes, such as after chemotherpay regimens or in chronic congenital neutropneia by providing novel biological active glycosylated G-CSF analogs.
    Type: Application
    Filed: February 19, 2003
    Publication date: December 16, 2004
    Inventors: John Michael Beals, Joe Christopher Berry, Marcia Kay Jones, Uma Kuchibhotla, Radhakrishnan Rathnachalam
  • Agents and methods for the treatment of proliferative diseases
    Publication number: 20030229026
    Abstract: The present invention provides selective kinase inhibitors of formula (I).
    Type: Application
    Filed: December 2, 2002
    Publication date: December 11, 2003
    Inventors: Rima Salim Al-Awar, Kyle Andrew Hecker, James Edward Ray, Jianping Huang, Sajan Joseph, Tiechao Li, Michael Paal, Radhakrishnan Rathnachalam, Chuan Shih, Philip Parker Waid, Xun Zhou, Guoxin Zhu